London, UK – 23 November 2011

Proximagen and Altacor sign agreement for 5HT2c.

2010 Annual Report

Proximagen’s 2010  Annual Report is now available to download.  To view the report, please click the link below.

Investor Relations

Our investor relations centre is provided to give you convenient access to company information.

Share Price

Proximagen Group plc (Ticker: PRX) is listed on the London Stock Exchange’s Alternative Investment Market.

Commitment to Science

Proximagen's commitment to science is fundamental. We strive for true scientific innovation in treatment.

Therapeutic Areas

Proximagen's aims to be one of the leading companies developing therapeutics in CNS, neuroinflammation, inflammation, and oncology.